TI
TVRD

Trexquant Investment’s Tvardi Therapeutics TVRD Stock Holding History

Trexquant Investment’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-311
Closed -$54.9K – 1875
2023
Q1 		$54.9K Buy
+311
New +$104K ﹤0.01% 1392
2022
Q2 		– Sell
-1,037
Closed -$454K – 1936
2022
Q1 		$454K Buy
+1,037
New +$426K 0.02% 806
2020
Q4 		– Sell
-421
Closed -$193K – 1574
2020
Q3 		$193K Buy
+421
New +$245K 0.01% 1089
2020
Q2 		– Sell
-434
Closed -$206K – 1551
2020
Q1 		$206K Buy
+434
New +$236K 0.01% 966
2016
Q3 		– Sell
-443
Closed -$77K – 1048
2016
Q2 		$77K Sell
443
-1,104
-71% -$240K 0.01% 826
2016
Q1 		$346K Buy
1,547
+339
+28% +$101K 0.04% 691
2015
Q4 		$733K Sell
1,208
-385
-24% -$211K 0.06% 527
2015
Q3 		$819K Buy
+1,593
New +$1.07M 0.07% 502

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trexquant Investment's TVRD Position: Q2 2023 in Review

Trexquant Investment sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 311 shares — an estimated $54.9K sold.

Trexquant Investment first reported a position in TVRD in Q3 2015 and held it in 8 quarters. The position peaked at $819K in Q3 2015. 136 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

  • Trexquant Investment reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Trexquant Investment sold 311 Tvardi Therapeutics shares in Q2 2023, an estimated $54.9K.
  • Trexquant Investment first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 8 quarters.
  • Trexquant Investment's Tvardi Therapeutics position peaked at $819K in Q3 2015.
  • 136 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on Trexquant Investment's 13F filing for Q2 2023, filed 11 Aug 2023.